Vulvovaginal Disease

In part 1 of this review, red flags for severe skin disease are discussed.

In a recent study, no severe adverse events were reported in women with vulvovaginal atrophy who were treated with a vaginal tamoxifen capsule.

A multi-targeted rapid sample processing and testing system has shown efficacy for diagnosing vulvovaginal candidiasis by detecting the presence of Candida species in women.

At the 2023 ACOG Annual Clinical & Scientific Meeting, a look at how AI and immunofluorescence scanning microscopy can help in detecting vaginitis and increase the health of the vaginal microbiome.

Three months ago, a healthy 2-year-old girl presented with a mildly pruritic rash with erythematous plaques, some silvery white, in the vulvovaginal area. She had no vaginal discharge or other symptoms. The rash is now more widespread, and new lesions have recently appeared on her lower back and thighs. What's the diagnosis?

The Xpert Xpress Multiplex Vaginal Panel test (Cephid) has shown high agreement for organisms causing vaginitis and vaginosis.

Becton, Dickinson and Company has announced its BD Vaginal Panel received 510(k) clearance from the FDA.

A new study suggests that ospemifene can reduce harmful bacteria and significantly contribute to vaginal health in postmenopausal women.

After observing an increase in the rate of syphilis cases, the Cleveland Clinic Ob/Gyn & Women’s Health Institute has partnered with the Center for Pediatric Infectious Diseases to evaluate the effectiveness of current testing strategies.

New research suggests that adding probiotics to established VVC treatment options may be a path to increased cure rates.

Ibrexafungerp (Brexafemme; Scynexis) is now approved for the treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

Bacterial vaginosis during pregnancy may lead to increased risks for preterm birth, preterm delivery, and spontaneous abortion, according to new research in the Archives of Gynecology and Obstetrics.

Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.

A study published in the journal Evidence-Based Complementary and Alternative Medicine found that both Nigella sativa (N. sativa) (black seed and black cumin)-honey vaginal cream and the antifungal medication clotrimazole significantly improve the symptoms of vulvovaginal candidiasis (VVC).

A research study examined the role of a medicated feminine wash as an adjunct treatment for candidiasis.

Three months after copper intrauterine device (IUD) insertion, nearly 1/3 of women were diagnosed with vulvovaginal candidiasis, compared to nearly 25% of women who received a hormonal IUD, according to a prospective study published in the journal Cellular and Molecular Biology.

The risk of vulvovaginal candidiasis (VVC) during pregnancy tends to peak in the third trimester, according to a review published in Infectious Diseases in Obstetrics and Gynecology. Risk factors range from contraceptive and antibiotic use to patients’ hygiene and overall health.1 With data regarding VVC and pregnancy incomplete and often conflicting, review authors say, more research is needed.

The medication also performed comparably to vulvovaginal candidiasis (VVC) standard-of-care fluconazole for treating acute VVC infection.

A study published in Frontiers in Immunology indicates that for the prognosis of recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (VVC), the host-immune responses, particularly Th1/2 immunity, may play a vital role.

The compound may also provide a synergistic effect in combination with fluconazole.

Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.

Correct terms and education can help normalize the conversation for patients.

If approved, ibrexafungerp would be the first and only approved therapy for both the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent vulvovaginal candidiasis (RVVC).

Mycovia Pharmaceuticals recently announced US availability of oteseconazole capsules for the treatment of recurrent vulvovaginal candidiasis in women without reproductive potential.

The CANDLE open-label sub-study enrolled 24 patients with RVVC who failed to respond to fluconazole treatment, which was given as an initial 3-dose treatment over 7 days.

Aerobic vaginitis (AV) in pregnant Vietnamese women correlated with a higher risk of puerperal sepsis and negative pregnancy outcomes.

Eradicating vaginal biofilms involving Candida species requires synergistic combinations of antifungal drugs with pre-, pro-, post-, and synbiotics, according to a recent Frontiers in Microbiology review.1

A cocktail of different probiotic species may be more effective than probiotic monotherapies, according to a recent literature review.

Results from this study can help increase understanding of the estimated incidence and lifetime prevalence of VVC in the US.